PRESS RELEASE

Investor Relations: Stamford, CT: +1 (203) 904 2410 Lausanne: +41 (0)58 242 4666 Email: InvestorRelations@pmi.com Media: David Fraser Lausanne: +41 (0)58 242 4500 Email: David.Fraser@pmi.com

Philip Morris International to Host Webcast of 2024 Fourth-Quarter and Full-Year Results

STAMFORD, CT – January 30, 2025 – Philip Morris International Inc. (PMI) (NYSE: PM) will host a live audio webcast at <u>www.pmi.com/2024Q4earnings</u> on Thursday, February 6, 2025, at 9:00 a.m. ET, to discuss its 2024 Fourth-Quarter and Full-Year financial results, which will be issued at approximately 7:00 a.m. ET the same day.

The webcast will be hosted by Jacek Olczak, Chief Executive Officer, and Emmanuel Babeau, Chief Financial Officer, and will include discussion of PMI's financial results and a Q&A session with the investment community. The webcast will be in a listen-only mode.

The webcast may also be accessed on mobile devices by downloading PMI's Investor Relations App at <u>www.pmi.com/irapp</u>.

The webcast recording and the slides and script will be available at <u>www.pmi.com/2024Q4earnings</u>. The recording will be available until 5:00 p.m. ET on Friday, March 7, 2025.

Philip Morris International: Delivering a Smoke-Free Future



PHILIP MORRIS INTERNATIONAL

Philip Morris International (PMI) is a leading international tobacco company, actively delivering a smoke-free future and evolving its portfolio for the long term to include products outside of the tobacco and nicotine sector. The company's current product portfolio primarily consists of cigarettes and smoke-free products. Since 2008, PMI has invested over \$12.5 billion to develop, scientifically substantiate and commercialize innovative smoke-free products for adults who would otherwise continue to smoke, with the goal of completely ending the sale of cigarettes. This includes the building of world-class scientific assessment capabilities, notably in the areas of pre-clinical systems toxicology, clinical and global smoke-free champion led by the companies' *IQOS* and *ZYN* brands. The U.S. Food and Drug Administration has authorized versions of PMI's *IQOS* devices and consumables and Swedish Match's *General* snus as Modified Risk Tobacco Products. Renewal applications for these *IQOS* products are pending before the FDA. As of June 30, 2024, PMI's smoke-free products. The smoke-free business accounted for approximately 38% of PMI's total first-nine months 2024 net revenues. With a strong foundation and significant expertise in life sciences, PMI has a long-term ambition to expand into wellness and healthcare areas and aims to enhance life through the delivery of seamless health experiences. References to "PMI", "we", "our" and "us" mean Philip Morris International Inc., including its subsidiaries. For more information, please visit <u>www.pmi.com</u> and <u>www.pmiscience.com</u>.